RecruitingPhase 3NCT06007690
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Studying Uveal melanoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Aura Biosciences
- Principal Investigator
- Medical MonitorAura Biosciences
- Intervention
- Bel-sar(drug)
- Enrollment
- 100 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2028
Study locations (30)
- Retina Consultants of Alabama, Birmingham, Alabama, United States
- UCSD Shiley Eye Institute, Jacobs Retina Center, La Jolla, California, United States
- Doris Stein Eye Research Center, Los Angeles, California, United States
- Stanford University School of Medicine, Palo Alto, California, United States
- Retinal Consultants Medical Group, Inc., Sacramento, California, United States
- Bascom Palmer Eye Institute, Miami, Florida, United States
- Retina Associates of Florida, PA, Tampa, Florida, United States
- Emory Eye Center, Atlanta, Georgia, United States
- University of Illinois at Chicago, Chicago, Illinois, United States
- Tufts Medical Center New England Eye Center, Boston, Massachusetts, United States
- Massachusetts Eye and Ear, Boston, Massachusetts, United States
- W.K. Kellogg Eye Center - University of Michigan, Ann Arbor, Michigan, United States
- Associated Retinal Consultants (ARC) P.C., Royal Oak, Michigan, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Washington University, St Louis, Missouri, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06007690 on ClinicalTrials.govOther trials for Uveal melanoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07364474Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the LiverMassachusetts General Hospital
- RECRUITINGPHASE3NCT07015190Neoadjuvant Darovasertib in Primary Uveal MelanomaIDEAYA Biosciences
- RECRUITINGPHASE2NCT07276386Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal MelanomaH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGPHASE1, PHASE2NCT06961357Clinical Trial of CD40L-augmented TIL for Patients With Advanced MelanomaH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGPHASE1NCT07203391Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell HomeostasisSt Vincent's Hospital, Sydney
- RECRUITINGPHASE1NCT07076550A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic MelanomaAlpha-9 Oncology USA Inc.
- RECRUITINGNCT07421739Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) SubjectsAura Biosciences
- RECRUITINGPHASE1, PHASE2NCT06626516Tebentafusp-tebn With LDT in Metastatic UMThomas Jefferson University